Neurocognitive Assessment in Youth Initiating HAART

Completed

Conditions studied: HIV Infections

In brief

ATN 071 is a prospective cohort study comparing neurocognitive functioning in four groups of youth, age 18-24: Two groups with CD4+ T cells above 350 cells/mm3 and HIV RNA \>1,000 copies/ml, one initiating HAART (Group 1) and the other not initiating treatment (Group 2); and two groups with CD4+ T cells \< 350 cells/mm3, one initiating treatment (Group 3) and the other not initiating treatment (Group 4). Groups 2 and 3 represent standard of care. Group 1 and a portion of group 2 will be co-enrolled in ATN 061 and will be randomly assigned to group by that protocol.

Key facts

Study ID: NCT00683579
Run by: University of North Carolina, Chapel Hill
People needed: 220
Starts: 2007-12-01
Expected to finish: 2013-06-01
Last updated by the study team: 2017-02-28

Who can join

Age: 18 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Groups 1 and 2 (If co-enrolling in ATN 061)
HIV positive participants age 18 years and 0 days to 24 years and 364 days (the lower age limit of this study is driven by the restriction of ATZ use to age 18 and greater);
Groups 1 and 2: CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml, as determined by two consecutive measures within 6 months of entry with the second measure being collected at pre-entry to ATN 061;
Infected with HIV after the age of nine via behavioral means;
Naïve to ART except for HAART for PMTCT for six months or less with at least six months since the time of exposure;
HIV genotype without major resistance mutations to the recommended ATV-r based HAART regimens;
Able to provide written informed consent as determined by local Institutional Review Boards;
Fluent in English or Spanish.
Group 2, enrolled in ATN 071 and not ATN 061
CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml, as determined by most recent laboratory evaluations available within 4 months prior to entry;
Not prescribed HAART according to DHHS guidelines.
Groups 3 and 4:
HIV positive participants age 18 years and 0 days to 24 years and 364 days;
Infected with HIV after the of age nine via behavioral means;
Naïve to ART except for HAART for PMTCT for six months or less with at least six months since the time of exposure;
Able to provide written informed consent as determined by local Institutional Review Boards;
Fluent in English or Spanish.
CD4+ T cells < 350 cells/mm3, as determined by most recent laboratory evaluations available within 4 months prior to entry.
Group 3 ONLY:
Participant initiating HAART.
Group 4 ONLY:
HAART has not been prescribed due to either participant's refusal to initiate HAART or provider's concerns about participant's predicted inability to adhere to regimen.

You may not qualify if…

Groups 1 and 2:
For Groups 1 and 2: any history of an AIDS-defining illness;
Active drug or alcohol use or dependence that, in the opinion of the site personnel, would interfere with meeting study requirements;
History of cognitive or motor impairment due to non-HIV-related conditions (for example, prematurity, cerebral palsy, closed head injury, CNS cancer or cranial irradiation, etc.) or psychosis. Youth with diagnoses of learning disabilities or attention deficit hyperactivity disorder will be allowed in the study;
Enrollment of youth with chronic or acute medical conditions other than HIV that could potentially impact upon neurocognitive functioning requires protocol chair approval.
Pregnancy at any time during the study including entry.

Where it is running

Children's Hopsital of Los Angeles — Los Angeles, California, United States
University of Southern California - IMPAACT Site — Los Angeles, California, United States
University of California at San Francisco — San Francisco, California, United States
Children's Hospital of Denver - IMPAACT Site — Aurora, Colorado, United States
Childrens National Medical Center — Washington D.C., District of Columbia, United States
Howard University - IMPAACT Site — Washington D.C., District of Columbia, United States
Children's Diagnostic and Treatment Center — Fort Lauderdale, Florida, United States
University of Miami School of Medicine — Miami, Florida, United States
University of South Florida — Tampa, Florida, United States
Stroger Hospital of Cook County — Chicago, Illinois, United States
Childrens Memorial Hospital — Chicago, Illinois, United States
Tulane University Health Sciences Center — New Orleans, Louisiana, United States
University of Maryland — Baltimore, Maryland, United States
Johns Hopkins University - IMPAACT Site — Baltimore, Maryland, United States
Children's Hospital of Michigan - IMPAACT Site — Detroit, Michigan, United States
Mount Sinai Medical Center — Manhattan, New York, United States
Montefiore Medical Center — The Bronx, New York, United States
Childrens Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
St. Jude Children's Research Center — Memphis, Tennessee, United States
St. Jude Children's Research Hospital - IMPAACT Site — Memphis, Tennessee, United States
University of Puerto Rico — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.